Paraben

Paraben

SCHEMBL1010571

O=C(O)c1ccc(O)cc1.[CaH2]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.94
CA1 P00915 3/20 0.94
CA12 O43570 1/20 0.94
CA3 P07451 1/20 0.94
TYR P14679 1/20 0.94
DRD1 P21728 1/20 0.94
CA4 P22748 1/20 0.94
CA6 P23280 1/20 0.94
CA5A P35218 1/20 0.94
CA7 P43166 1/20 0.94
CA9 Q16790 1/20 0.94
CA14 Q9ULX7 1/20 0.94
CA5B Q9Y2D0 1/20 0.94
SRD5A2 P31213 3/20 0.80
TSHR P16473 3/20 0.71
TP53 P04637 1/20 0.71
ESR1 P03372 1/20 0.60
ESR2 Q92731 1/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Paraben SCHEMBL7622776 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Paraben SCHEMBL20500516 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Terephthalic Acid SCHEMBL6692916 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Paraben SCHEMBL5311518 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Terephthalic Acid SCHEMBL3460105 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Paraben SCHEMBL3212865 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Paraben SCHEMBL4110 0.97 CA2 (1.00) CA2CA1CA12CA3TYR
Paraben SCHEMBL2488395 0.94 CA2 (0.94) CA2CA1CA12CA3TYR
Paraben SCHEMBL21061691 0.94 CA2 (0.94) CA2CA1CA12CA3TYR
Paraben SCHEMBL10606180 0.94 CA2 (0.94) CA2CA1CA12CA3TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230363380-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2023-11-16 US claimed
US-20220079145-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2022-03-17 US claimed
US-20180077925-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2018-03-22 US claimed
CN-107635589-A Essentially antimicrobial porous matrix composites and methods of making the same 约翰·保罗·威尔逊 2018-01-26 CN claimed
EP-3265135-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF Wilson, John Paul (US) 2018-01-10 EP claimed
WO-2016144907-A1 INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF WILSON JOHN PAUL (US) 2016-09-15 WO claimed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 EP claimed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 US claimed
EP-3592329-B1 USE OF COMPATIBLE SOLUTES SUSONITY Commercial GmbH (DE) 2026-02-18 EP disclosed
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent SYMRISE AG (DE) 2026-02-12 US disclosed
US-12545860-B2 Mannanase variants BASF SE (DE) 2026-02-10 US disclosed
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection SYMRISE AG (DE) 2026-02-05 US disclosed
EP-4676433-A1 LIQUID UV FILTER CONCENTRATE Symrise AG (DE) 2026-01-14 EP disclosed
EP-4676428-A1 LIQUID UV FILTER COMPOSITION CONTAINING DIOLS Symrise AG (DE) 2026-01-14 EP disclosed
WO-2004092283-A2 ANTIMICROBIAL PIGMENTS MERCK PATENT GMBH (DE) 2004-10-28 WO disclosed
WO-2004091567-A2 COSMETIC FORMULATIONS COMPRISING ANTIMICROBIAL PIGMENTS MERCK PATENT GMBH (DE) 2004-10-28 WO disclosed
WO-2004087740-A2 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORPORATION (US) 2004-10-14 WO disclosed
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto PROCYTE CORPORATION 2004-10-07 US disclosed
US-6800671-B1 UNSATURATED COMPOUND, ADHESION PROMOTER AND CURING AGENT; FLEXIBLE BIOADHESIVES BRITESMILE, INC. 2004-10-05 US disclosed
WO-2001081437-A1 LOW PEAK EXOTHERM CURABLE COMPOSITIONS BRITESMILE, INC. (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent TLR7, MYC, ERG28 CA2 4525/4885CA1 4875/4885CA12 4850/4885
US-12545860-B2 Mannanase variants MAN2A1, MANBA, IDUA CA2 4162/4885CA1 4163/4885CA12 3172/4885
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto AOC1, NONO, CUTA CA2 1848/4885CA1 890/4885CA12 1650/4885
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection TYR, ERG28, CUTA CA2 4757/4885CA1 4868/4885CA12 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.